UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 271

Sortiert nach

Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S82-S82

2017

Volltextzugriff (PDF)

AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients

Journal of hepatology, 2016, Vol.64 (2), p.S404-S405

2016

Volltextzugriff (PDF)

Pan-Genotypic Evaluation of AL-335, a Clinical Stage Uridine Analogue Inhibitor of Hepatitis C Virus Polymerase

Journal of hepatology, 2016, Vol.64 (2), p.S404-S404

2016

Volltextzugriff (PDF)

P0682 : Preclinical characterization of AL-335, a potent uridine based nucleoside polymerase inhibitor for the treatment of chronic hepatitis C

Journal of hepatology, 2015-04, Vol.62, p.S577-S578

2015

Volltextzugriff (PDF)

P0679 : Derisking the potential for mitochondrial toxicity of nucleoside analogs

Journal of hepatology, 2015-04, Vol.62, p.S576-S577

2015

Volltextzugriff (PDF)

1219 VX-135, A POTENT SINGLE DIASTEREOMER OF ALS-2200, FOR THE TREATMENT OF CHRONIC HEPATITIS C

Journal of hepatology, 2013-04, Vol.58, p.S495-S495

2013

Volltextzugriff (PDF)

866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C

Journal of hepatology, 2013-04, Vol.58, p.S355-S355

2013

Volltextzugriff (PDF)

1222 IN VITRO RESISTANCE TO ALS-2200, A POTENT NUCLEOTIDE POLYMERASE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS C

Journal of hepatology, 2013-04, Vol.58, p.S496-S496

2013

Volltextzugriff (PDF)

19 DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY

Journal of hepatology, 2008, Vol.48, p.S10-S10

2008

Volltextzugriff (PDF)

Rescue of Abasic Hammerhead Ribozymes by Exogenous Addition of Specific Bases

Proceedings of the National Academy of Sciences - PNAS, 1996-10, Vol.93 (21), p.11522-11527

1996

Volltextzugriff (PDF)

Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance

The Journal of biological chemistry, 1995-10, Vol.270 (43), p.25702-25708

1995

Volltextzugriff (PDF)

938 DISCOVERY OF POTENT, BIOAVAILABLE HCV NS3/4A INHIBITORS THAT DISPLAY UNIMPAIRED ACTIVITY AGAINST AN NS3 SEQUENCE VARIANT ASSOCIATED WITH RESISTANCE TO LINEAR TETRAPEPTIDES AND MACROCYCLIC INHIBITORS

Journal of hepatology, 2009, Vol.50, p.S341-S341

2009

Volltextzugriff (PDF)

Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure

Nucleic acids research, 1996-02, Vol.24 (4), p.573

1996

Volltextzugriff (PDF)

Synthesis of 2′-O-Substituted Ribonucleosides

Nucleosides, nucleotides & nucleic acids, 2003-10, Vol.22 (5-8), p.1007-1009

2003

Volltextzugriff (PDF)

PS-153 - Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S82-S82

2017

Volltextzugriff (PDF)

Identification of the Hammerhead Ribozyme Metal Ion Binding Site Responsible for Rescue of the Deleterious Effect of a Cleavage Site Phosphorothioate

Biochemistry (Easton), 1999-10, Vol.38 (43), p.14363-14378

1999

Volltextzugriff (PDF)

Comparison of the hammerhead cleavage reactions stimulated by monovalent and divalent cations

RNA (Cambridge), 2001-04, Vol.7 (4), p.537-545, Article S1355838201002461

2001

Volltextzugriff (PDF)

Synthesis of 1,4-Anhydro-2-deoxy-D-ribitol Derivatives from Thymidine

Nucleosides, nucleotides & nucleic acids, 2003-10, Vol.22 (5-8), p.1305-1307

2003

Volltextzugriff (PDF)

THU-226 - Pan-Genotypic Evaluation of AL-335, a Clinical Stage Uridine Analogue Inhibitor of Hepatitis C Virus Polymerase

Journal of hepatology, 2016, Vol.64 (2), p.S404-S404

2016

Volltextzugriff (PDF)

Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA

Journal of viral hepatitis, 2002-11, Vol.9 (6), p.411-418

2002

Volltextzugriff (PDF)

THU-228 - AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients

Journal of hepatology, 2016, Vol.64 (2), p.S404-S405

2016

Volltextzugriff (PDF)

Nuclease-Resistant Ribozymes Decrease Stromelysin mRNA Levels in Rabbit Synovium Following Exogenous Delivery to the Knee Joint

Proceedings of the National Academy of Sciences - PNAS, 1996-01, Vol.93 (2), p.754-758

1996

Volltextzugriff (PDF)

An Improved Synthesis of Inosine 3′-Phosphoramidite

Synthetic communications, 2000-11, Vol.30 (21), p.3963-3969

2000

Volltextzugriff (PDF)

An efficient preparation of protected ribonucleosides for phosphoramidite RNA synthesis

Tetrahedron letters, 2002-03, Vol.43 (11), p.1983-1985

2002

Volltextzugriff (PDF)

The Structural Basis of Hammerhead Ribozyme Self-Cleavage

Cell, 1998-03, Vol.92 (5), p.665-673

1998

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(205)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis

AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients

Pan-Genotypic Evaluation of AL-335, a Clinical Stage Uridine Analogue Inhibitor of Hepatitis C Virus Polymerase

P0682 : Preclinical characterization of AL-335, a potent uridine based nucleoside polymerase inhibitor for the treatment of chronic hepatitis C

P0679 : Derisking the potential for mitochondrial toxicity of nucleoside analogs

1219 VX-135, A POTENT SINGLE DIASTEREOMER OF ALS-2200, FOR THE TREATMENT OF CHRONIC HEPATITIS C

866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C

1222 IN VITRO RESISTANCE TO ALS-2200, A POTENT NUCLEOTIDE POLYMERASE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS C

19 DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY

Rescue of Abasic Hammerhead Ribozymes by Exogenous Addition of Specific Bases

Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance

938 DISCOVERY OF POTENT, BIOAVAILABLE HCV NS3/4A INHIBITORS THAT DISPLAY UNIMPAIRED ACTIVITY AGAINST AN NS3 SEQUENCE VARIANT ASSOCIATED WITH RESISTANCE TO LINEAR TETRAPEPTIDES AND MACROCYCLIC INHIBITORS

Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure

Synthesis of 2′-O-Substituted Ribonucleosides

PS-153 - Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis

Identification of the Hammerhead Ribozyme Metal Ion Binding Site Responsible for Rescue of the Deleterious Effect of a Cleavage Site Phosphorothioate

Comparison of the hammerhead cleavage reactions stimulated by monovalent and divalent cations

Synthesis of 1,4-Anhydro-2-deoxy-D-ribitol Derivatives from Thymidine

THU-226 - Pan-Genotypic Evaluation of AL-335, a Clinical Stage Uridine Analogue Inhibitor of Hepatitis C Virus Polymerase

Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA

THU-228 - AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients

Nuclease-Resistant Ribozymes Decrease Stromelysin mRNA Levels in Rabbit Synovium Following Exogenous Delivery to the Knee Joint

An Improved Synthesis of Inosine 3′-Phosphoramidite

An efficient preparation of protected ribonucleosides for phosphoramidite RNA synthesis

The Structural Basis of Hammerhead Ribozyme Self-Cleavage

Suchergebnisse filtern